The world ophthalmic drugs market will reach $20.9BN in 2014

Friday 9 May 2014, Amsterdam

$ The new report predicts that the world market for ophthalmic drugs will reach $20.9bn in 2014. This forecast and others appear in Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024.

Ophthalmic drugs are drugs used to treat eye diseases such as glaucoma, age-related macular degeneration (AMD), allergic conjunctivitis, and dry eye disease. This niche sector of the pharmaceutical industry is dominated by a small number of companies but retains high growth potential in some disease areas in 2014-2024. The ophthalmic drugs market has also been transformed in recent years by the impact of generic prostaglandin analogues for treating glaucoma, the challenge to Roche’s blockbuster Lucentis from Regeneron’s wet AMD drug, Eylea, and by Valeant Pharmaceuticals’ $8.7bn-acquisition of leading eye care company Bausch and Lomb.

Thomas Ling, a pharmaceutical and medical devices industry analyst, said: “The ophthalmic drugs market is expected to grow strongly during 2014-2024. This growth will be driven by the increasing prevalence of many eye diseases, especially glaucoma, AMD and diabetic retinopathy, as well as the launch of new drugs and formulations to address the huge unmet need for treatments to prevent visual loss. While the glaucoma segment is seeing a negative impact on revenues due to generic latanoprost, revenues in all major segments of the ophthalmic drugs market are set to increase over the forecast period. In 2013 we are also seeing a higher concentration of market share and pipeline products among a small number of leading companies, in keeping with long-term trends in the pharma industry towards increasing the R&D specialisation of research-based pharma companies. However, companies with truly innovative therapies for patients in this market can expect to reap great rewards, making ophthalmic drugs a fast-moving and rapidly changing market.”

The new report new 235 page report contains 152 tables, charts and graphs that add visual analysis in order to explain developing trends within the global ophthalmic drugs market. The new study provides revenue forecasts to 2024 for the world ophthalmic drugs market and leading submarkets. It forecasts sales for the glaucoma, retinal disorders, allergy / inflammatory / infective and dry eye segments of the market. The report also analyses the top 25 leading companies in the ophthalmic drugs market including [alpha list of companies]. It also discusses key marketed products, products in the development pipeline, commercial news, and analysis of strengths, weaknesses, opportunities and threats. It includes interviews with industry experts regarding current market trends. The report also includes a Porter’s Five Forces analysis to understand the degree of competitiveness in this market.

Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024 adds to the range of analytical reports on industries and markets in healthcare.

This report will be of value to current and future potential investors into the ophthalmic drugs market, as well as companies and research centres who wish to broaden their knowledge of the industry.